Skip to Content

Advanced Search

Login
|
Create a Profile
|
Quick Order
|
(0 items)
|
USA

Select another country:

|
1.800.638.6597

NCI-H209 [H209] (ATCC^® HTB-172^™)

Organism: Homo sapiens, human / Tissue: lung; derived from metastatic site: bone marrow / Disease: carcinoma; small cell lung cancer (SCLC)

NCI-H209 [H209] ATCC^® HTB-172^™

frozen

For-Profit: $431.00 Non-Profit: $366.35

Qty:

Permits and Restrictions	View Permits View Restrictions
Organism	Homo sapiens, human
Tissue	lung; derived from metastatic site: bone marrow
Product Format	frozen
Morphology	epithelial
Culture Properties	aggregates in suspension
Biosafety Level	1 Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease	carcinoma; small cell lung cancer (SCLC)
Gender	male
Ethnicity	Caucasian
Storage Conditions	liquid nitrogen vapor phase

Karyotype	This is a hyperdiploid human cell line., The modal chromosome number is 49, occurring at 28% with a frequency of higher ploidies of 1.3%. Ten to eleven markers were common to all cells including: der(1)t(1;3)(p22;p21), del(6)(q21), t(8q18q), del(12)(q13), der(14)t(14;?)(q32;?)., All had a single copy per cell. About 6 other markers were found, but they occurred only once in all metaphases karyotyped. Neither HSR nor DM were detected., Structurally normal B group chromosomes were not detected. All C group chromosomes were paired. A single copy of both the X and Y was found in all cells.
Derivation	The NCI-H209 cell line was derived by A.F. Gazdar and associates in 1979 from the bone marrow of a patient with small cell cancer of the lung.
Clinical Data	The bone marrow specimen was taken prior to therapy.
Oncogene	pRB + (abnormal, RB1)
Tumorigenic	Yes
Effects	Yes, forms transplantable tumors with typical SCLC histology in nude mice
Comments	C-myc DNA sequences are not amplified. No gross structural DNA abnormalities were detected. This is a cell line that grows as large aggregates in suspension. Only the aggregates are viable, but no meaningful viability percentage can be measured. The medium will normally contain large amounts of cell debris. The cells express an aberrant form of RB1 that is not phosphorylated, apparently due to a single point mutation at codon 706 (Cys -> Phe). The line is a classic SCLC cell line which expresses elevated levels of four biochemical markers (neuron specific enolase, brain isoenzyme of creatine kinase, L-DOPA decarboxylase and bombesin-like immunoreactivity. The line produces normal amounts of p53 mRNA relative to normal lung.

Complete Growth Medium	Iscove's modified Dulbecco's medium, 90%; fetal bovine serum, 10% - OR - RPMI 1640 medium, 90%; fetal bovine serum, 10%
Subculturing	The line should be subcultured by dilution with fresh medium. Alternatively, the clusters may be collected by centrifugation and resuspended in fresh medium. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended Medium Renewal: 2 to 3 times per week
Cryopreservation	Culture medium, 95%; DMSO, 5%

STR Profile	Amelogenin: X,Y CSF1PO: 11 D13S317: 11 D16S539: 9,12 D5S818: 12 D7S820: 9 THO1: 7,9 TPOX: 8 vWA: 18,19
Isoenzymes	AK-1, 1 ES-D, 1 G6PD, B Me-2, 0 PGM1, 1-2 PGM3, 1

Name of Depositor	AF Gazdar, JD Minna
Deposited As	Homo sapiens
References	Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201 Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494 Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370 Kaye FJ, et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87: 6922-6926, 1990. PubMed: 2168563 Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760 Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024
Cross References	Nucleotide (GenBank) : A93403 Sequence 1 from Patent WO9741834. Nucleotide (GenBank) : A93404 Sequence 2 from Patent WO9741834.

Permits	These permits may be required for shipping this product: Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation	Product Sheet Certificate of Analysis SDS
Restrictions	The line is available with the following restrictions: This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. Any proposed commercial use of the these cells, or their products, must first be negotiated with the National Cancer Institute (NCI). For further information, please contact NCI’s Technology Transfer Center at NCI_TTC_Contact@mail.nih.gov or by phone at (240)-276-5514.
References	Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201 Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494 Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370 Kaye FJ, et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87: 6922-6926, 1990. PubMed: 2168563 Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760 Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024